Theravance Biopharma, Inc. Restructuring Reserve
Theravance Biopharma, Inc. (TBPH) had Restructuring Reserve of $14.00 thousand as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2023-08-09
- 2023-06-30: Restructuring Reserve $14.00K.
- 2023-03-31: Restructuring Reserve $618.00K.
- 2022-06-30: Restructuring Reserve $592.00K.
- 2022-03-31: Restructuring Reserve $3.40M.
| Period end | Restructuring Reserve |
|---|---|
| 2023-06-30 | $14.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $618.00K 10-Q · filed 2023-05-10 |
| 2022-06-30 | $592.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.40M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $9.55M 10-K · filed 2023-03-01 |
| 2021-09-30 | $1.77M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |